Venous Stent for the Iliofemoral Vein Investigational Clinical Trial Using the DUO Venous Stent System

Completed · Not applicable

Conditions studied: May-Thurner Syndrome, Deep Vein Thrombosis, Chronic Venous Insufficiency

In brief

This is a prospective, multi-center, single-arm, non-blinded clinical trial designed to investigate the safety and efficacy of the Vesper DUO Venous Stent System as compared to a pre-defined performance goal (PG) established from published, peer reviewed scientific literature related to stenting of iliofemoral venous outflow obstructions.

Key facts

Study ID

NCT04580160

Run by

Vesper Medical, Inc.

People needed

162

Starts

2020-11-30

Expected to finish

2025-04-15

Last updated by the study team

2025-05-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or non-pregnant, non-breastfeeding females ≥18 years of age at the time of consent
• Subject is able and willing to provide written informed consent prior to receiving any non-standard of care, protocol specific procedures
• Female subjects of childbearing potential must have a negative pregnancy test within 7 days prior to treatment and must use some form of contraception (abstinence is acceptable) throughout the time of clinical trial exit
• Willing and capable of complying with all required follow-up visits
• Estimated life expectancy ≥1 year
• Subject is ambulatory (use of assistive walking device such as a cane or walker is acceptable)
• Body mass index (BMI) <40
• Clinically significant symptomatic venous outflow obstruction in one iliofemoral venous segment (one limb) per subject, is indicated for venoplasty and stenting, and meets at least one of the following clinical indicators:
• Clinical-Etiology-Anatomy-Pathophysiology (CEAP) score ≥3
• Venous Clinical Severity Score (VCSS) pain score ≥2
• Suspected deep vein thrombosis (DVT) with symptoms occurring prior to receiving a DUO Stent
• Subject is willing and able to comply with PI recommendation for compression therapy, if required
• Presence of unilateral, non-malignant venous obstruction of the common femoral vein (CFV), external iliac vein (EIV), common iliac vein (CIV), or any combination thereof, defined as a ≥50% reduction in target vessel lumen diameter and confirmed by venographic or IVUS imaging. The cranial point of the obstruction may extend to the iliac vein confluence of the inferior vena cava (IVC) and the caudal point may be 2mm above either the inflow of the deep femoral (or profunda) or the lesser trochanter, whichever is most cranial
• Obstructive lesion(s) able to be treated with continuous stent coverage
• Adequate inflow to the target lesion(s) involving at least a patent femoral or deep femoral vein and a landing zone in the CFV free from significant disease requiring treatment
• Reference vessel diameter is of adequate size to accommodate the appropriate size stent as measured by IVUS
• All vessels from insertion site through target vessel can accommodate a 9F or 10F sheath, depending on the stent size used
• Ability to cross interventional devices through target lesion(s)
• In DVT subjects, successful treatment of acute thrombus must have occurred prior to receiving any DUO Stents for an underlying obstructive lesion. Successful treatment of acute thrombus is defined as reestablishment of antegrade flow with ≤30% residual thrombus (confirmed by venogram or IVUS) and freedom from bleeding and symptomatic pulmonary embolism (confirmed by imaging). After successful treatment of thrombus is confirmed, eligible obstructive lesion(s) can be treated with a DUO Stent during the same procedure.
• All subjects must undergo a SARS-CoV-2 test and have a negative test result within 8 days of the index procedure. If a SARS-CoV-2 test is unavailable due to institution policy, a test shortage, or if there is a delay in test results, the subject must complete the COVID-19 questionnaire and must have answered NO to all questions to be eligible for enrollment. A SARS-CoV-2 test will not be required for enrollment if a subject has received a complete cycle of an authorized COVID-19 vaccine or has documented evidence of a positive COVID-19 antibody test and is asymptomatic and has no long-lasting effects (per PI discretion) from a prior COVID-19 infection.
• A measured temperature less than 99.5°F (37.5°C) on the day of the index procedure and no history of fever or feeling feverish within 14 days of the index procedure
• No prior history, within 60 days of the index procedure, of a SARS-CoV-2 positive test, or COVID-19 symptoms

You may not qualify if…

• Target limb symptoms caused by peripheral arterial disease
• Presence of unresolved significant pulmonary embolism prior to use of the DUO Venous Stent System confirmed by chest CT. If subject has documented history of significant pulmonary embolism within the last 6 months, a chest CT is required to confirm significant pulmonary embolism is not currently present.
• Presence of IVC obstruction or target venous obstruction that extends into the IVC
• Presence of acute DVT located outside target limb
• Contralateral venous occlusive disease of the CFV, EIV, and/or CIV, with planned treatment ≤390 days after the index procedure
• Uncontrolled or active coagulopathy or known, uncorrectable bleeding diathesis
• Coagulopathy causing INR >2 which is not amenable to medical treatment
• Platelet count <50,000 cells/mm3 or >1,000,000 cells/mm3 and/or White blood cell (WBC) <3,000 cells/mm3 or >12,500 cells/mm3
• Uncorrected hemoglobin of ≤9 g/dL
• Subject is on dialysis or has an estimated glomerular filtration rate (eGFR) <30 mL/min. In subjects with diabetes mellitus, eGFR <45 mL/min.
• History of Heparin Induced Thrombocytopenia
• Presence of known aggressive clotting disorders such as Lupus Anticoagulant Disorder, Antiphospholipid antibody syndrome, homozygous gene Factor V Leiden or Prothrombin gene abnormalities, Protein C and S deficiency or Antithrombin deficiency
• Known hypersensitivity or contraindication to antiplatelet therapy or anticoagulation, nickel, or titanium
• Contrast agent allergy that cannot be managed adequately with pre-medication
• Intended concurrent adjuvant procedure (except for venoplasty) such as creation of temporary arteriovenous fistula, femoral endovenectomy or saphenous vein ablation and/or saphenous vein stripping during the index procedure
• Subjects who have had any prior surgical or endovascular procedures to the target vessel. Note that subjects who have had successful catheter-directed or mechanical thrombolysis in the target vessel for DVT at least 90 days prior to the index procedure may be included
• Planned surgical or interventional procedures of the target limb (except thrombolysis and/or thrombectomy in preparation for the procedure or vena cava filter placement prior to stent implantation in subjects at high risk for pulmonary embolism) within 30 days prior to or 30 days after the index procedure
• Planned surgical or interventional procedures for other medical conditions (i.e., not associated with the target limb) 30 days prior to or 30 days after the index procedure
• Previous venous stenting of the target limb, the IVC, or contralateral limb if stents extend into the IVC
• Iliofemoral venous segment unsuitable for treatment with available sizes of DUO Stent implants
• Lesions with intended treatment lengths extending into the IVC
• No safe landing zone at or above the profunda femoral confluence
• Participating in another investigational study in which the subject has not completed the primary endpoint(s)
• Has other comorbidities that, in the opinion of the Investigator, would preclude them from receiving this treatment and/or participating in study-required follow-up assessments

Where it is running

• St. Joseph Hospital — Orange, California, United States
• Stanford University — Palo Alto, California, United States
• The Vascular Experts — Darien, Connecticut, United States
• Hartford Hospital — Hartford, Connecticut, United States
• MedStar Washington Hospital Center — Washington D.C., District of Columbia, United States
• Mount Sinai Medical Center of Florida — Miami, Florida, United States
• Palm Vascular Centers — Miami Beach, Florida, United States
• University Clinical Research-Deland LLC — Winter Park, Florida, United States
• Piedmont Atlanta Hospital — Atlanta, Georgia, United States
• Northwestern University — Chicago, Illinois, United States
• Midwest Cardiovascular Research Foundation — Davenport, Iowa, United States
• Cardiovascular Institute of the South — Opelousas, Louisiana, United States
• Michigan Outpatient Vascular Institute — Dearborn, Michigan, United States
• Edgewood Hospital and Medical Center — Englewood, New Jersey, United States
• Holy Name Medical Center — Teaneck, New Jersey, United States
• Icahn School of Medicine at Mount Sinai — New York, New York, United States
• Columbia University Irving Medical Center — New York, New York, United States
• Stony Brook Medicine — Stony Brook, New York, United States
• Atrium Health — Charlotte, North Carolina, United States
• The Ohio Health Research Institute — Columbus, Ohio, United States
• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
• The Miriam Hospital — Providence, Rhode Island, United States
• Houston Healthcare Medical Center — Houston, Texas, United States
• North Dallas Research Associates — McKinney, Texas, United States
• Hurricane Cardiology Research — New Braunfels, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.